These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1748 related articles for article (PubMed ID: 22665537)
21. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. Natkunam Y; Farinha P; Hsi ED; Hans CP; Tibshirani R; Sehn LH; Connors JM; Gratzinger D; Rosado M; Zhao S; Pohlman B; Wongchaowart N; Bast M; Avigdor A; Schiby G; Nagler A; Byrne GE; Levy R; Gascoyne RD; Lossos IS J Clin Oncol; 2008 Jan; 26(3):447-54. PubMed ID: 18086797 [TBL] [Abstract][Full Text] [Related]
22. Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable. Landsburg DJ; Falkiewicz MK; Petrich AM; Chu BA; Behdad A; Li S; Medeiros LJ; Cassaday RD; Reddy NM; Bast MA; Vose JM; Kruczek KR; Smith SE; Patel P; Hernandez-Ilizaliturri F; Karmali R; Rajguru S; Yang DT; Maly JJ; Blum KA; Zhao W; Vanslambrouck C; Nabhan C Br J Haematol; 2016 Nov; 175(4):631-640. PubMed ID: 27469075 [TBL] [Abstract][Full Text] [Related]
23. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma. Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232 [TBL] [Abstract][Full Text] [Related]
24. Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. Scott DW; Mottok A; Ennishi D; Wright GW; Farinha P; Ben-Neriah S; Kridel R; Barry GS; Hother C; Abrisqueta P; Boyle M; Meissner B; Telenius A; Savage KJ; Sehn LH; Slack GW; Steidl C; Staudt LM; Connors JM; Rimsza LM; Gascoyne RD J Clin Oncol; 2015 Sep; 33(26):2848-56. PubMed ID: 26240231 [TBL] [Abstract][Full Text] [Related]
25. A population-based study of cellular markers in R-CHOP treated diffuse large B-cell lymphoma patients. Abdulla M; Laszlo S; Triumf J; Hedström G; Berglund M; Enblad G; Amini RM Acta Oncol; 2016; 55(9-10):1126-1131. PubMed ID: 27549735 [TBL] [Abstract][Full Text] [Related]
26. Prognostic Significance of Rosenwald A; Bens S; Advani R; Barrans S; Copie-Bergman C; Elsensohn MH; Natkunam Y; Calaminici M; Sander B; Baia M; Smith A; Painter D; Pham L; Zhao S; Ziepert M; Jordanova ES; Molina TJ; Kersten MJ; Kimby E; Klapper W; Raemaekers J; Schmitz N; Jardin F; Stevens WBC; Hoster E; Hagenbeek A; Gribben JG; Siebert R; Gascoyne RD; Scott DW; Gaulard P; Salles G; Burton C; de Jong D; Sehn LH; Maucort-Boulch D J Clin Oncol; 2019 Dec; 37(35):3359-3368. PubMed ID: 31498031 [TBL] [Abstract][Full Text] [Related]
27. Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma. Landsburg DJ; Petrich AM; Abramson JS; Sohani AR; Press O; Cassaday R; Chavez JC; Song K; Zelenetz AD; Gandhi M; Shah N; Fenske TS; Jaso J; Medeiros LJ; Yang DT; Nabhan C Cancer; 2016 Feb; 122(4):559-64. PubMed ID: 26565895 [TBL] [Abstract][Full Text] [Related]
28. Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen. Nakamura N; Goto N; Tsurumi H; Takemura M; Kanemura N; Kasahara S; Hara T; Yasuda I; Shimizu M; Sawada M; Yamada T; Seishima M; Takami T; Moriwaki H Eur J Haematol; 2013 Oct; 91(4):322-31. PubMed ID: 23672298 [TBL] [Abstract][Full Text] [Related]
29. Primary extranodal diffuse large B-cell lymphomas: Many sites, many entities? Clinico-pathological, immunohistochemical and cytogenetic study of 106 cases. Magnoli F; Bernasconi B; Vivian L; Proserpio I; Pinotti G; Campiotti L; Mazzucchelli L; Sessa F; Tibiletti MG; Uccella S Cancer Genet; 2018 Dec; 228-229():28-40. PubMed ID: 30553470 [TBL] [Abstract][Full Text] [Related]
30. The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma. Xia Y; Zhang X Acta Haematol; 2020; 143(6):520-528. PubMed ID: 32074595 [TBL] [Abstract][Full Text] [Related]
31. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP. Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569 [TBL] [Abstract][Full Text] [Related]
33. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296 [TBL] [Abstract][Full Text] [Related]
34. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy. Li ZM; Huang JJ; Xia Y; Zhu YJ; Zhao W; Wei WX; Jiang WQ; Lin TY; Huang HQ; Guan ZZ Eur J Haematol; 2012 Jun; 88(6):510-7. PubMed ID: 22413767 [TBL] [Abstract][Full Text] [Related]
35. Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study. Tzankov A; Leu N; Muenst S; Juskevicius D; Klingbiel D; Mamot C; Dirnhofer S J Hematol Oncol; 2015 Jun; 8():70. PubMed ID: 26071053 [TBL] [Abstract][Full Text] [Related]
36. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. Ennishi D; Jiang A; Boyle M; Collinge B; Grande BM; Ben-Neriah S; Rushton C; Tang J; Thomas N; Slack GW; Farinha P; Takata K; Miyata-Takata T; Craig J; Mottok A; Meissner B; Saberi S; Bashashati A; Villa D; Savage KJ; Sehn LH; Kridel R; Mungall AJ; Marra MA; Shah SP; Steidl C; Connors JM; Gascoyne RD; Morin RD; Scott DW J Clin Oncol; 2019 Jan; 37(3):190-201. PubMed ID: 30523716 [TBL] [Abstract][Full Text] [Related]
37. A success story: how a single targeted-therapy molecule impacted on treatment and outcome of diffuse large B-cell lymphoma. Mian M; Augustin F; Kocher F; Gunsilius E; Willenbacher W; Zabernigg A; Zangerl G; Oexle H; Schreieck S; Schnallinger M; Fiegl M Anticancer Res; 2014 May; 34(5):2559-64. PubMed ID: 24778077 [TBL] [Abstract][Full Text] [Related]
38. Prevalence and clinicopathologic features of CD30-positive de novo diffuse large B-cell lymphoma in Chinese patients: a retrospective study of 232 cases. Gong QX; Lu TX; Liu C; Wang Z; Liang JH; Xu W; Li JY; Zhang ZH; Chen Q Int J Clin Exp Pathol; 2015; 8(12):15825-35. PubMed ID: 26884853 [TBL] [Abstract][Full Text] [Related]
39. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824 [TBL] [Abstract][Full Text] [Related]
40. The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab. Meyer PN; Fu K; Greiner T; Smith L; Delabie J; Gascoyne R; Ott G; Rosenwald A; Braziel R; Campo E; Vose J; Lenz G; Staudt L; Chan W; Weisenburger DD Am J Clin Pathol; 2011 Jan; 135(1):54-61. PubMed ID: 21173124 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]